Drug
Quadrivalent Seasonal Influenza Vaccine Gsk2282512a
Quadrivalent Seasonal Influenza Vaccine Gsk2282512a: highest development phase Phase 3, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Quadrivalent seasonal influenza vaccine GSK2282512A NCT01198756 | Phase 3 | Influenza |
Latest
No recent events.
Follow Quadrivalent Seasonal Influenza Vaccine Gsk2282512a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.